The Rosen Law Firm, P.A. announces that it has filed a class action lawsuit on behalf of purchasers of MiMedx Group, Inc. (NASDAQ: MDXG) securities during the period from March 15, 2013 to September 4, 2013 inclusive (the “Class Period”), seeking to recover damages for violations of the federal securities laws.
To join the MiMedx class action, visit the firm’s website at
, or call Phillip Kim, Esq. or Kevin Chan, toll-free, at 866-767-3653; you may also email at
for information on the class action. The lawsuit is pending in the U.S. District Court for the Southern District of New York.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the suit, MiMedx issued materially false and misleading statements about whether its AmnioFix product required U.S. Food and Drug Administration (“FDA”) approval to be manufactured and marketed. On September 4, 2013, MiMedx confirmed that it received an “Untitled Letter” from the FDA. The letter stated that MiMedx’s Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing drugs at one of its plants, and thereby marketed unapproved biologics products. The lawsuit asserts that this adverse information caused the price of MiMedx’s securities to fall—damaging investors.
If you wish to serve as lead plaintiff, you must move the Court no later than November 8, 2013. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan of The Rosen Law Firm, toll-free, at 866-767-3653, or via e-mail at
. You may also visit the firm’s website at
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.